Bloch Itai, Quintana Francisco J, Gerber Doron, Cohen Tomer, Cohen Irun R, Shai Yechiel
Department of Biological Chemistry, the Weizmann Institute of Science, Rehovot, 76100 Israel.
FASEB J. 2007 Feb;21(2):393-401. doi: 10.1096/fj.06-7061com. Epub 2006 Dec 21.
Fusion peptide (FP) of the HIV gp41 molecule inserts into the T cell membrane during virus-cell fusion. FP also blocks the TCR/CD3 interaction needed for antigen-triggered T cell activation. Here we used in vitro (fluorescence and immunoprecipitation), in vivo (T cell mediated autoimmune disease adjuvant arthritis), and in silico methods to identify the FP-TCR novel interaction motif: the alpha-helical transmembrane domain (TMD) of the TCR alpha chain, and the beta-sheet 5-13 region of the 16 N-terminal aa of FP (FP(1-16)). Deciphering the molecular mechanism of the immunosuppressive activity of FP provides a new potential target to overcome the immunosuppressant activity of HIV, and in addition a tool for down-regulating immune mediated inflammation.
HIV gp41分子的融合肽(FP)在病毒与细胞融合过程中插入T细胞膜。FP还阻断抗原触发的T细胞活化所需的TCR/CD3相互作用。在这里,我们使用体外(荧光和免疫沉淀)、体内(T细胞介导的自身免疫性疾病佐剂性关节炎)和计算机模拟方法来鉴定FP-TCR新型相互作用基序:TCRα链的α螺旋跨膜结构域(TMD),以及FP(1-16)的16个N端氨基酸的β折叠5-13区域。解读FP免疫抑制活性的分子机制为克服HIV的免疫抑制活性提供了一个新的潜在靶点,此外还提供了一种下调免疫介导炎症的工具。